ATE501173T1 - Anti-ip-10-antikörper - Google Patents

Anti-ip-10-antikörper

Info

Publication number
ATE501173T1
ATE501173T1 AT04800979T AT04800979T ATE501173T1 AT E501173 T1 ATE501173 T1 AT E501173T1 AT 04800979 T AT04800979 T AT 04800979T AT 04800979 T AT04800979 T AT 04800979T AT E501173 T1 ATE501173 T1 AT E501173T1
Authority
AT
Austria
Prior art keywords
antibodies
present
directed
subject
human
Prior art date
Application number
AT04800979T
Other languages
English (en)
Inventor
Balaji Balasa
Naoya Tsurushita
Nicolas Landolfi
Original Assignee
Abbott Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/014507 external-priority patent/WO2004101511A2/en
Application filed by Abbott Biotherapeutics Corp filed Critical Abbott Biotherapeutics Corp
Priority claimed from PCT/US2004/037600 external-priority patent/WO2005060457A2/en
Application granted granted Critical
Publication of ATE501173T1 publication Critical patent/ATE501173T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/30—Hydrogen technology
    • Y02E60/32—Hydrogen storage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT04800979T 2003-12-04 2004-11-10 Anti-ip-10-antikörper ATE501173T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52788203P 2003-12-04 2003-12-04
PCT/US2004/014507 WO2004101511A2 (en) 2003-05-09 2004-05-07 Anti-ip-10 antibodies and methods of using thereof for the treatment of inflamatory bowel diseases
PCT/US2004/037600 WO2005060457A2 (en) 2003-12-04 2004-11-10 Treatment of inflammatory bowel diseases with anti-ip-10 antibodies

Publications (1)

Publication Number Publication Date
ATE501173T1 true ATE501173T1 (de) 2011-03-15

Family

ID=43646212

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04800979T ATE501173T1 (de) 2003-12-04 2004-11-10 Anti-ip-10-antikörper

Country Status (3)

Country Link
US (1) US7935793B2 (de)
AT (1) ATE501173T1 (de)
DE (1) DE602004031772D1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1691837T3 (pl) * 2003-12-10 2012-11-30 Squibb & Sons Llc IP-10 przeciwciała i ich zastosowanie
CA2678626A1 (en) 2007-02-28 2008-09-04 Novimmune S.A. Anti-ip-10 antibodies and methods of use thereof
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US20120321687A1 (en) * 2010-02-19 2012-12-20 University Of Virginia Patent Foundation Compositions and methods for using and identifying antimicrobial agents
EA201390472A1 (ru) 2010-10-29 2014-02-28 Иммьюноджен, Инк. Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
EA201390575A1 (ru) 2010-10-29 2014-01-30 Иммьюноджен, Инк. Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
CN103619880A (zh) 2011-04-29 2014-03-05 百时美施贵宝公司 Ip-10抗体剂量递增方法
CA2856411A1 (en) 2011-11-21 2013-05-30 Immunogen, Inc. Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
KR101452865B1 (ko) * 2012-09-17 2014-10-21 서울대학교산학협력단 신규한 ｉｐ－１０ 에피토프 및 이에 대한 항체
WO2017043466A1 (ja) * 2015-09-08 2017-03-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ＥｐｈＡ４抗体
WO2017095875A1 (en) 2015-11-30 2017-06-08 Bristol-Myers Squibb Company Anti human ip-10 antibodies and their uses
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (de) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Behandlung einer erkrankung des gastrointestinaltraktes mit einem chemokin/chemokin-rezeptor-inhibitor
EP3883635A1 (de) 2018-11-19 2021-09-29 Progenity, Inc. Verfahren und vorrichtungen zur behandlung einer krankheit mit biotherapeutika
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN111339181B (zh) * 2020-02-10 2021-08-06 腾讯科技（深圳）有限公司 区块存储方法、装置、节点设备及存储介质
CN114656561B (zh) * 2022-03-05 2023-06-09 南京鼓楼医院 一种抗ip-10单克隆抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3246079A1 (de) 1982-12-13 1984-06-14 Umbach, Albert, 3436 Hessisch Lichtenau Schleifgeraet, insbesondere zum schleifen von zaehnen von kettensaegen
FR2556219B1 (fr) * 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
IT1181800B (it) 1984-12-19 1987-09-30 Fercad Spa Affilatore a mola rotante particolarmente per seghe a catena per tronchi d'albero
US7297478B1 (en) * 2000-09-22 2007-11-20 Large Scale Biology Corporation Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules

Also Published As

Publication number Publication date
US7935793B2 (en) 2011-05-03
DE602004031772D1 (de) 2011-04-21
US20080063646A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
ATE501173T1 (de) Anti-ip-10-antikörper
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
WO2004070011A3 (en) HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
LTC2041177I2 (lt) Didelio giminingumo antikūnai prieš žmogaus IL-6 receptorių
NO20074867L (no) Antistoffer mot CCR5 og anvendelser derav
NZ599683A (en) Anti-ilt7 antibody
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
PE20110801A1 (es) Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f
EA200870050A1 (ru) Анти-il-17-антитела
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
RU2008132968A (ru) Антитела к рецептору тимусного стромального лимфопоэтина
DK1425389T3 (da) Interleukin-15-(IL-15)-specifikke humane antistoffer
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
WO2006099698A3 (en) Novel anti-plgf antibody
PE20141398A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
MX2009009194A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes.
DK1802658T3 (da) Kimære og humaniserede monoklonale antistoffer mod interleukin-13
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
JP2009525758A5 (de)
DK1716181T3 (da) CDR-reparerede antistoffer
BR112012007365A2 (pt) proteínas de ligação à il-1
PE20061323A1 (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
NZ712762A (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
NO20080800L (no) Kimaere antistoffer med New World primat regioner

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties